1. World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis. 2008, [http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/] Accessed 29/12/2013
2. Caminero JA: Guidelines for clinical and operational management of drug-resistant tuberculosis. International Union Against Tuberculosis and Lung Disease Paris, France. 2013, http://www.theunion.org/what-we-do/publications/technical/english/mdr-tbguide_6-19-13_web.pdf Accessed 29/12/2013
3. Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, Da Silva E, Khan S, Paryani R, Udwadia Z, Migliori GB, Sotgiu G, Reid T: Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012, 7 (7): e40781-10.1371/journal.pone.0040781.
4. Francis J: Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Second Edition. Edited by: Loeffler AM. 2011, San Francisco, California, USA
5. Marc D, Olson K: Hypersensitivity reactions and methods of detection. 2009, Neurosci. Inc, 1-4. [http://neurorelief.info/uploads/content_files/Hypersensitivity Reactions and Methods of Detection.pdf] Accessed 29/12/2013